Aclaris Therapeutics (ACRS) Short Interest Ratio & Short Volume $1.38 -0.01 (-0.36%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aclaris Therapeutics Short Interest DataAclaris Therapeutics (ACRS) has a short interest of 4.07 million shares, representing 6.09% of the float (the number of shares available for trading by the public). This marks a -34.78% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.5, indicating that it would take 4.5 days of the average trading volume of 1.18 million shares to cover all short positions.Current Short Interest4,070,000 sharesPrevious Short Interest6,240,000 sharesChange Vs. Previous Month-34.78%Dollar Volume Sold Short$4.56 millionShort Interest Ratio4.5 Days to CoverLast Record DateApril 15, 2025Outstanding Shares108,281,000 sharesShort Percent of Float6.09%Today's Trading Volume178,053 sharesAverage Trading Volume1,183,685 sharesToday's Volume Vs. Average15% Short Selling Aclaris Therapeutics? Sign up to receive the latest short interest report for Aclaris Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartACRS Short Interest Over TimeACRS Days to Cover Over TimeACRS Percentage of Float Shorted Over Time Aclaris Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20254,070,000 shares $4.56 million -34.8%6.1%4.5 $1.12 3/31/20256,240,000 shares $9.55 million +3.5%9.3%6.9 $1.53 3/15/20256,030,000 shares $9.41 million +26.7%9.0%6.5 $1.56 2/28/20254,760,000 shares $9.47 million -5.2%7.1%5.8 $1.99 2/15/20255,020,000 shares $11.70 million +28.1%7.5%5 $2.33 1/31/20253,920,000 shares $9.72 million +15.6%N/A1.6 $2.48 1/15/20253,390,000 shares $8.51 million -4.8%N/A1.3 $2.51 12/31/20243,560,000 shares $8.83 million +12.7%N/A1.5 $2.48 12/15/20243,160,000 shares $10.18 million +27.4%N/A1.4 $3.22 11/30/20242,480,000 shares $10.09 million +59.0%N/A1.1 $4.07 Get the Latest News and Ratings for ACRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20241,560,000 shares $3.20 million -35.3%N/A0.7 $2.05 10/31/20242,410,000 shares $4.36 million +73.4%N/A4.6 $1.81 10/15/20241,390,000 shares $1.64 million -19.7%N/A4.1 $1.18 9/30/20241,730,000 shares $1.99 million +1.2%N/A3.6 $1.15 9/15/20241,710,000 shares $2.02 million -0.6%N/A2.4 $1.18 8/31/20241,720,000 shares $2.03 million -4.4%N/A2.2 $1.18 8/15/20241,800,000 shares $2.12 million -3.2%N/A2.2 $1.18 7/31/20241,860,000 shares $2.49 million -13.9%N/A2.1 $1.34 7/15/20242,160,000 shares $2.92 million -45.2%N/A2.4 $1.35 6/30/20243,940,000 shares $4.33 million -11.7%N/A4.7 $1.10 6/15/20244,460,000 shares $5.26 million -3.3%N/A6.5 $1.18 5/31/20244,610,000 shares $4.75 million -5.3%N/A6.3 $1.03 5/15/20244,870,000 shares $5.75 million -18.2%N/A5.4 $1.18 4/30/20245,950,000 shares $7.20 million +19.2%N/A5.6 $1.21 4/15/20244,990,000 shares $6.04 million +2.0%N/A4.5 $1.21 3/31/20244,890,000 shares $6.06 million -4.5%N/A3 $1.24 3/15/20245,120,000 shares $5.99 million -16.1%N/A2.9 $1.17 2/29/20246,100,000 shares $7.26 million +4.6%N/A2.8 $1.19 2/15/20245,830,000 shares $7.17 million -7.9%N/A2.4 $1.23 1/31/20246,330,000 shares $7.34 million -0.5%N/A1.3 $1.16 1/15/20246,360,000 shares $5.88 million +9.8%N/A1.3 $0.92 12/31/20235,790,000 shares $6.08 million -2.0%N/A1.3 $1.05 12/15/20235,910,000 shares $5.97 million +24.2%N/A1.4 $1.01 11/30/20234,760,000 shares $4.16 million -35.6%N/A1.1 $0.87 11/15/20237,390,000 shares $5.92 million +12.3%N/A2 $0.80 10/31/20236,580,000 shares $32.77 million +8.8%N/A6.5 $4.98 10/15/20236,050,000 shares $32.19 million +2.0%N/A7.2 $5.32 9/30/20235,930,000 shares $40.62 million -9.1%N/A7.8 $6.85 9/15/20236,520,000 shares $49.23 million +14.4%N/A9.1 $7.55 8/31/20235,700,000 shares $42.64 million +10.5%N/A8.3 $7.48Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 8/15/20235,160,000 shares $40.09 million -1.0%N/A8.4 $7.77 7/31/20235,210,000 shares $51.42 million +4.2%N/A8.7 $9.87 7/15/20235,000,000 shares $54.75 million -5.3%N/A7.9 $10.95 6/30/20235,280,000 shares $54.75 million +14.0%N/A8.2 $10.37 6/15/20234,630,000 shares $45.88 million -2.7%N/A6.5 $9.91 5/31/20234,760,000 shares $39.75 million +2.4%N/A6.8 $8.35 5/15/20234,650,000 shares $38.69 million -5.3%N/A4.5 $8.32 4/30/20234,910,000 shares $43.65 million -1.4%9.8%4.4 $8.89 4/15/20234,980,000 shares $44.02 million +3.8%9.9%4.4 $8.84 3/31/20234,800,000 shares $38.83 million +14.8%9.5%4.4 $8.09 3/15/20234,180,000 shares $33.40 million +26.7%8.1%4.2 $7.99 2/28/20233,300,000 shares $41.12 million +8.9%6.4%3.7 $12.46 2/15/20233,030,000 shares $39.66 million +14.3%5.9%5.4 $13.09 1/31/20232,650,000 shares $44.79 million -6.7%5.2%5.8 $16.90 1/15/20232,840,000 shares $50.98 million -5.0%5.5%8.1 $17.95 12/30/20222,990,000 shares $47.09 million +12.4%5.8%9 $15.75 12/15/20222,660,000 shares $41.63 million -4.0%5.2%7.9 $15.65 11/30/20222,770,000 shares $42.16 million -14.0%5.4%7.8 $15.22 11/15/20223,220,000 shares $57.90 million -12.5%6.3%9.4 $17.98 10/31/20223,680,000 shares $57.44 million -4.9%7.1%10.9 $15.61 10/15/20223,870,000 shares $60.84 million +7.2%7.5%11.4 $15.72 9/30/20223,610,000 shares $56.82 million +9.4%7.0%11.3 $15.74 9/15/20223,300,000 shares $47.49 million +5.1%6.4%9.5 $14.39 8/31/20223,140,000 shares $49.96 million -10.0%6.1%8.9 $15.91 8/15/20223,490,000 shares $58.49 million -1.4%6.8%9.8 $16.76 7/31/20223,540,000 shares $54.55 million -9.0%N/A9.3 $15.41 7/15/20223,890,000 shares $59.28 million +3.2%N/A10.2 $15.24 6/30/20223,770,000 shares $52.63 million +5.6%N/A7.9 $13.96 6/15/20223,570,000 shares $52.66 million +1.4%N/A7.2 $14.75 5/31/20223,520,000 shares $45.02 million +37.5%6.9%7.5 $12.79 5/15/20222,560,000 shares $27.26 million +20.2%5.0%5.3 $10.65 4/30/20222,130,000 shares $26.24 million -8.6%4.5%4.3 $12.32 4/15/20222,330,000 shares $39.63 million -16.2%5.0%4.6 $17.01 3/31/20222,780,000 shares $47.93 million +2.2%6.0%5.9 $17.24 3/15/20222,720,000 shares $41.34 million +3.4%5.8%6 $15.20 2/28/20222,630,000 shares $39.19 million +14.4%5.6%5.7 $14.90 2/15/20222,300,000 shares $29.30 million +10.6%4.9%4.9 $12.74 1/31/20222,080,000 shares $22.71 million +7.8%4.8%4.7 $10.92 1/15/20221,930,000 shares $20.86 million -5.9%4.1%4.6 $10.81 12/31/20212,050,000 shares $29.81 million +0.5%4.3%5.3 $14.54 12/15/20212,040,000 shares $27.97 million +8.5%4.3%4.9 $13.71 11/30/20211,880,000 shares $24.06 million -0.5%4.0%4.3 $12.80 11/15/20211,890,000 shares $27.48 million -15.3%4.0%4.3 $14.54 10/29/20212,230,000 shares $38.69 million -19.2%4.9%5.3 $17.35 10/15/20212,760,000 shares $46.40 million -14.3%6.1%6.7 $16.81 9/30/20213,220,000 shares $57.96 million +9.2%7.1%7.3 $18.00 9/15/20212,950,000 shares $52.24 million +8.1%6.5%5.4 $17.71 8/31/20212,730,000 shares $44.25 million -12.8%6.0%4.4 $16.21 8/13/20213,130,000 shares $46.07 million +0.6%7.0%4.5 $14.72 7/30/20213,110,000 shares $46.43 million -11.4%6.4%4.3 $14.93Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 7/15/20213,510,000 shares $53.07 million -13.1%7.4%4.6 $15.12 6/30/20214,040,000 shares $70.94 million +61.0%9.3%5.2 $17.56 6/15/20212,510,000 shares $44.70 million +32.8%5.8%3.5 $17.81 5/28/20211,890,000 shares $42.03 million No Change4.9%2.7 $22.24 5/14/20211,890,000 shares $40.14 million +9.9%4.9%3.2 $21.24 4/30/20211,720,000 shares $42.90 million +16.2%4.7%2.6 $24.94 4/15/20211,480,000 shares $41.17 million +62.4%4.1%1.8 $27.82 3/31/2021911,100 shares $21.48 million +41.5%2.5%0.3 $23.58 3/15/2021644,000 shares $16.24 million -15.2%1.8%0.2 $25.21 2/26/2021759,000 shares $16.11 million -47.7%1.9%0.3 $21.22 2/12/20211,450,000 shares $33.74 million +52.7%3.9%0.5 $23.27 1/29/2021949,600 shares $18.54 million +69.1%2.7%0.3 $19.52 1/15/2021561,500 shares $3.43 million -18.4%1.6%0.2 $6.10 12/31/2020688,200 shares $4.56 million +42.2%2.2%1.1 $6.62 12/15/2020484,000 shares $1.90 million -12.8%1.6%0.7 $3.93 11/30/2020555,300 shares $1.84 million -9.4%1.8%1.4 $3.32 11/15/2020613,200 shares $2.23 million -10.1%2.0%1.5 $3.64 10/30/2020682,300 shares $2.61 million +5.7%2.2%1.6 $3.83 10/15/2020645,400 shares $2.58 million -6.7%2.0%1.3 $4.00 9/30/2020691,500 shares $1.78 million +17.0%2.1%1.1 $2.57 9/15/2020591,100 shares $1.39 million -12.0%1.8%0.9 $2.35 8/31/2020671,700 shares $1.65 million -19.7%2.1%0.8 $2.46 8/14/2020836,700 shares $2.06 million -12.3%2.6%1 $2.46 7/31/2020953,500 shares $2.05 million -23.1%3.0%1.2 $2.15 7/15/20201,240,000 shares $2.52 million -9.5%4.0%1.8 $2.03 6/30/20201,370,000 shares $2.19 million -21.7%4.4%2.6 $1.60 6/15/20201,750,000 shares $2.54 million +0.6%5.6%4.1 $1.45 5/29/20201,740,000 shares $2.33 million -11.2%5.5%6.1 $1.34 5/15/20201,960,000 shares $2.53 million -7.1%6.2%6.2 $1.29 ACRS Short Interest - Frequently Asked Questions What is Aclaris Therapeutics' current short interest? Short interest is the volume of Aclaris Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 4,070,000 shares of ACRS short. 6.09% of Aclaris Therapeutics' shares are currently sold short. Learn More on Aclaris Therapeutics' current short interest. What is a good short interest ratio for Aclaris Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ACRS shares currently have a short interest ratio of 4.0. Learn More on Aclaris Therapeutics's short interest ratio. Which institutional investors are shorting Aclaris Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aclaris Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Aclaris Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.09% of Aclaris Therapeutics' floating shares are currently sold short. Is Aclaris Therapeutics' short interest increasing or decreasing? Aclaris Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 4,070,000 shares, a decline of 34.8% from the previous total of 6,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Aclaris Therapeutics' short interest compare to its competitors? 6.09% of Aclaris Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aclaris Therapeutics: Akebia Therapeutics, Inc. (8.56%), Tyra Biosciences, Inc. (12.81%), GH Research PLC (7.12%), Cullinan Therapeutics, Inc. (22.53%), Relay Therapeutics, Inc. (11.46%), Stoke Therapeutics, Inc. (26.73%), Sage Therapeutics, Inc. (8.06%), Maravai LifeSciences Holdings, Inc. (5.56%), MeiraGTx Holdings plc (3.37%), UroGen Pharma Ltd. (22.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Aclaris Therapeutics stock? Short selling ACRS is an investing strategy that aims to generate trading profit from Aclaris Therapeutics as its price is falling. ACRS shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aclaris Therapeutics? A short squeeze for Aclaris Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ACRS, which in turn drives the price of the stock up even further. How often is Aclaris Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACRS, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies AKBA Short Interest TYRA Short Interest GHRS Short Interest CGEM Short Interest RLAY Short Interest STOK Short Interest SAGE Short Interest MRVI Short Interest MGTX Short Interest URGN Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ACRS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts